Rexahn Pharmaceuticals is a clinical-stage ophthalmic biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye disorders. With a clear focus on retinal and refractive eye disorders, they aim to address both front and back of the eye indications. Their pipeline includes two exciting small-molecule product candidates.

The first is APX3330, an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases like diabetic retinopathy and macular edema. APX3330 has shown promising results in six Phase 1 and five Phase 2 trials. The second candidate is Nyxol®, a versatile eye drop being developed to treat pharmacologically-induced mydriasis, presbyopia, and dim light or night vision disturbances.

Nyxol® has been studied extensively in 12 completed Phase 1, 2, and 3 trials, involving over 650 subjects. Rexahn Pharmaceuticals is also actively seeking partnerships to expand their vision even further by acquiring additional ophthalmic assets and collaborating on late-stage development, regulatory preparation, and commercialization of drugs in global markets. With a leadership team composed of experienced professionals in the medical research and biotech industries, Rexahn Pharmaceuticals is poised to make a significant impact in the field of eye care